Tag: PD-L1
Stunning Progress Achieved in Lung Cancer Treatment Over the Last Decade
By Kara Nyberg, PhD
Posted: April 16, 2020
After decades of failed clinical trials and persistently dismal lung cancer survival outcomes, the 2010s breathed new life...
PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC...
By Sylvie Lantuejoul, MD, PhD, and Mari Mino-Kenudson, MD
Posted: April 16, 2020
Immune checkpoint inhibitors (ICI), which target the PD-1/PD-L1 axis with the aim of...
CheckMate 568: Efficacy and Biomarker Analysis for Nivolumab and Ipilimumab in...
By Neal Ready, MD, PhD
Posted: February 12, 2020
Programmed death receptor (PD-1) checkpoint monoclonal antibody therapy has proven a major advancement in the management of...
PD-L1 in Cytology Specimens
By Anjali Saqi, MD, MBA; Deepali Jain, MD, FIAC; Lukas Bubendorf, MD; Keith Kerr, MB, ChB, MRCPath, FRCPath, FRCP(Ed); and Andre Moreira, MD, PhD
Posted:...
Concurrent Chemoradiation Followed by Consolidation Therapy: Questions Remain Despite Transformational Data
Posted: November 12, 2019
Now that data from the PACIFIC trial have been incorporated into daily practice, similar trials are validating the results or taking...
Global Survey for Pathologists on PD-L1 Testing: Moving Toward Standardization
By Mari Mino-Kenudson, MD, and Sylvie Lantuejoul, MD, PhD
Posted: November 12, 2019
Determination of PD-L1 expression by immunohistochemistry (IHC) has been widely evaluated in clinical...
